About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Bcap31tm1.1Bwang
targeted mutation 1.1, Bing Wang
MGI:6368552
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Bcap31tm1.1Bwang/Bcap31tm1.1Bwang
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 MGI:6714084
cn2
Bcap31tm1.1Bwang/Bcap31tm1.1Bwang
Tg(Lck-cre)548Jxm/0
involves: C57BL/6 * CBA MGI:6719029


Genotype
MGI:6714084
cn1
Allelic
Composition
Bcap31tm1.1Bwang/Bcap31tm1.1Bwang
Lyz2tm1(cre)Ifo/Lyz2+
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcap31tm1.1Bwang mutation (0 available); any Bcap31 mutation (8 available)
Lyz2tm1(cre)Ifo mutation (14 available); any Lyz2 mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• increased number of Iba1-labeled activated microglia in the hippocampal CA1 and dentate gurus (DG) areas after intracerebroventricular (i.c.v.) LPS administration
• increased Il1b mRNA levels in the hippocampus after i.c.v. LPS administration
• increased IL-1beta protein levels in primary microglial cells after LPS administration for 24 h
• increased Tnf mRNA levels in the hippocampus after i.c.v. LPS administration
• increased TNF protein levels in primary microglial cells after LPS administration for 24 h
• increased mRNA expression of proinflammatory factors (Tnf, Il1b, Nos2 and Ptgs2) in the hippocampus after i.c.v. LPS administration

nervous system
• increased number of Iba1-labeled activated microglia in the hippocampal CA1 and dentate gurus (DG) areas after intracerebroventricular (i.c.v.) LPS administration
• decreased number of NeuN-labeled intact neurons in the hippocampal CA1 and dentate gurus (DG) areas after i.c.v. LPS administration

homeostasis/metabolism
• increased Nos2 (nitric oxide synthase 2, inducible; aka iNOS) and Ptgs2 (prostaglandin-endoperoxide synthase 2; aka cyclooxygenase-2, Cox2) mRNA levels in the hippocampus following i.c.v. LPS administration

behavior/neurological
N
• no alterations in spontaneous locomotor activity (total moving distance) in the open field test 7 days after i.c.v. LPS administration at 2 months of age
• mice exhibit severe deficits in spatial memory formation after i.c.v. LPS administration
• in the Morris water maze test, the escape latency on training day 3, 4 and 5 is longer in LPS-treated mice relative to that in LPS-treated controls; in the probe test, LPS-treated mice show a reduced number of platform-site crossings, travel a shorter distance and spend less time in the target quadrant than LPS-treated controls
• in the Y-maze test, LPS-treated mice show a reduced number of alterations but no change in the total number of arm entries relative to LPS-treated controls

hematopoietic system
• increased number of Iba1-labeled activated microglia in the hippocampal CA1 and dentate gurus (DG) areas after intracerebroventricular (i.c.v.) LPS administration




Genotype
MGI:6719029
cn2
Allelic
Composition
Bcap31tm1.1Bwang/Bcap31tm1.1Bwang
Tg(Lck-cre)548Jxm/0
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcap31tm1.1Bwang mutation (0 available); any Bcap31 mutation (8 available)
Tg(Lck-cre)548Jxm mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• accelerated apoptosis in freshly isolated thymocytes after tunicamycin treatment
• decreased thymus size in young adult (3-, 5- or 8-week-old) and older mice (6-month-old)
• decreased thymus weight in young adult and older mice
• reduced total thymocyte number in young adult and older mice
• however, development of double-negative (DN) thymocytes and CD4+ and CD8+ single-positive (SP) thymocytes is normal
• no significant change in DN1-4 thymic subsets
• decreased % of naive (CD44lowCD62Lhi) in CD4+ and CD8+ T cells in the spleen and lymph nodes of young adult (8-wk-old) and older mice (6-mo-old)
• increased % of effector/memory T cells (CD44hiCD62Llo) in CD4+ and CD8+ T cells in the spleen and lymph nodes of young adult (8-wk-old) and older mice (6-mo-old)
• decreased percentage of CD4+ and CD8+ single positive (SP) mature T lymphocytes in the spleen and lymph nodes of young adult (3-, 5- or 8-week-old) and older mice (6-month-old)
• decreased percentage of CD4+ and CD8+ T cells in peripheral blood
• however, expression of class I MHC molecules on CD4+ and CD8+ SP splenocytes is normal
• marked reduction in IL-2 and IFN-gamma production following stimulation of total splenocytes with anti-CD3 plus anti-CD28
• reduced T cell proliferation following stimulation of total splenocytes with anti-CD3 plus anti-CD28
• marked reduction in IFN-gamma production following stimulation of total splenocytes with anti-CD3 plus anti-CD28; also detected at the mRNA level
• marked reduction in IL-2 production following stimulation of total splenocytes with anti-CD3 plus anti-CD28; also detected at the mRNA level

hematopoietic system
• accelerated apoptosis in freshly isolated thymocytes after tunicamycin treatment
• decreased thymus size in young adult (3-, 5- or 8-week-old) and older mice (6-month-old)
• decreased thymus weight in young adult and older mice
• reduced total thymocyte number in young adult and older mice
• however, development of double-negative (DN) thymocytes and CD4+ and CD8+ single-positive (SP) thymocytes is normal
• no significant change in DN1-4 thymic subsets
• decreased % of naive (CD44lowCD62Lhi) in CD4+ and CD8+ T cells in the spleen and lymph nodes of young adult (8-wk-old) and older mice (6-mo-old)
• increased % of effector/memory T cells (CD44hiCD62Llo) in CD4+ and CD8+ T cells in the spleen and lymph nodes of young adult (8-wk-old) and older mice (6-mo-old)
• decreased percentage of CD4+ and CD8+ single positive (SP) mature T lymphocytes in the spleen and lymph nodes of young adult (3-, 5- or 8-week-old) and older mice (6-month-old)
• decreased percentage of CD4+ and CD8+ T cells in peripheral blood
• however, expression of class I MHC molecules on CD4+ and CD8+ SP splenocytes is normal
• marked reduction in IL-2 and IFN-gamma production following stimulation of total splenocytes with anti-CD3 plus anti-CD28
• reduced T cell proliferation following stimulation of total splenocytes with anti-CD3 plus anti-CD28

cellular
• accelerated apoptosis in freshly isolated thymocytes after tunicamycin treatment
• reduced T cell proliferation following stimulation of total splenocytes with anti-CD3 plus anti-CD28

endocrine/exocrine glands
• accelerated apoptosis in freshly isolated thymocytes after tunicamycin treatment
• decreased thymus size in young adult (3-, 5- or 8-week-old) and older mice (6-month-old)
• decreased thymus weight in young adult and older mice
• reduced total thymocyte number in young adult and older mice
• however, development of double-negative (DN) thymocytes and CD4+ and CD8+ single-positive (SP) thymocytes is normal
• no significant change in DN1-4 thymic subsets





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
05/07/2024
MGI 6.23
The Jackson Laboratory